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The complexity of recombinant protein manufacturing processes, including 
expression systems (i.e. host cell line, expression vector, cell line engineering process), 
cell culture process conditions, and choice of media and feeds, present significant 
challenges to achieve desired product quality of biopharmaceuticals. Significantly more 
challenging is to develop processes for biosimilar proteins, which must match product 
quality attributes of the originator molecule, show comparable in-vitro biological activity, 
and have no clinically meaningful differences as compared to innovator products. To 
address these challenges, and provide appropriate, flexible, and quick solutions to 
govern product quality control during manufacturing, Fujifilm Diosynth Biotechnologies 
(FDB) has developed a unique systematic approach of combining “Media Toolbox” 
methodology, key chemical components, and cell culture bioprocess “know-how” to 
optimize and control manufacturing conditions that promote the desired product quality 
profiles of recombinant proteins.  
 
Case studies will be presented to highlight the efficacy of this approach. Case 1 
represents a successful application of the “Media Toolbox” consisting of high-quality 
media and feeds targeting a variety of CHO parental cell lines that we have established 
from FDB Innovation program. By using this methodology to optimize a Phase 3 
manufacturing process, in less than 3 months, we not only improved the mAb titers ~ 5-
fold (> 5 g/L) as compared to original cell culture process, but matched the key product 
quality attributes including all examined glycan structures and demonstration of scale 
reproducibility from bench-scale (2L, 10L bioreactors) to manufacturing scale (2000L 
bioreactor). In addition, on the top of the “Media Toolbox”, the “know-how” of nutrient 
components (i.e. sugars, trace elements) and cell culture process conditions further 
expand the ability to optimize and control product quality in a “targeted” manner. This 
will be outlined with a couple of case studies, to highlight how this concept impacts 
Glycan structures and functions (i.e. the balance between G0 and G1 glycoforms and 
relationship with the ADCC). 
